GENMAB A/S
Close on Oct 19, 2026
About Genmab A/S
Pharmaceutical Preparations, SIC 2834
Genmab A/S is a biotechnology company focused on developing antibody-based therapeutics for the treatment of diseases, primarily targeting cancer indications such as multiple myeloma. The company creates proprietary antibody technologies and therapies while also collaborating with pharmaceutical partners to develop, acquire, and commercialize products, including daratumumab and investigational candidates like petosemtamab and Rina-S. Its treatments are designed for healthcare systems, physicians, and patient populations requiring specialized therapies, including patients who have failed prior therapies.
Headquartered in Valby within the municipality of Copenhagen, Denmark, the company conducts its operations internationally, with clinical trials and commercial distribution spanning regions including the United States, Europe, and Japan. The company operates research and clinical programs encompassing multiple phase II and phase III clinical studies across targeted territories.
Summary of the business section of Genmab A/S's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GENMAB A/S
- Headquarters
- 1253 Copenhagen K, G7
- Address
- Toldbodgade 33 00000
- Employees
- 3,029, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Auditor
- Deloitte, Copenhagen
Stock & identifiers
- Ticker
- GMAB
- Other tickers
- GNMSF
- Exchange
- Nasdaq
- IPO date
- Jul 19, 2019
- Shares outstanding
- 129M, Dec 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 5-for-1, May 1, 2018
- SEC CIK
- 1434265
- CUSIP
- 372303206
- ISIN
- US3723032062
- LEI
- 529900MTJPDPE4MHJ122
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Genmab A/S's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of December 31, 2025 , we had 3,029 employees; 556 in Denmark, 946 in the Netherlands, 1,158 in the US, 220 in”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 21, 2025 | Tender offer | Third-party tender offer for the company's shares |
| Jul 19, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 12, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |